Nanobiotix S.A. (EPA:NANO)
France · Delayed Price · Currency is EUR 18.22
-0.30 (-1.62%)
Oct 7, 2025, 5:35 PM CET
Nanobiotix Employees
Nanobiotix had 108 employees as of December 31, 2024. The number of employees increased by 6 or 5.88% compared to the previous year.
Employees
108
Change (1Y)
6
Growth (1Y)
5.88%
Revenue / Employee
€98,631
Profits / Employee
€501,388
Market Cap
878.47M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 108 | 6 | 5.88% |
| Dec 31, 2023 | 102 | 0 | - |
| Dec 31, 2022 | 102 | 2 | 2.00% |
| Dec 31, 2021 | 100 | 10 | 11.11% |
| Dec 31, 2020 | 90 | -20 | -18.18% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| EssilorLuxottica Société anonyme | 153,498 |
| Sanofi | 82,878 |
| Sartorius Stedim Biotech | 9,901 |
| bioMérieux | 14,754 |
| Eurofins Scientific SE | 62,696 |
| Ipsen | 5,358 |
| ABIVAX Société Anonyme | 69 |
| Virbac | 6,365 |
Nanobiotix News
- 5 days ago - Nanobiotix (NBTX) Sees Stock Rise on Promising Cancer Drug Trial Results - GuruFocus
- 5 days ago - Nanobiotix gains after early-stage trial data for J&J-partnered cancer drug - Seeking Alpha
- 5 days ago - Top 2 Health Care Stocks That May Keep You Up At Night This Month - Benzinga
- 6 days ago - NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer - GlobeNewsWire
- 6 days ago - Nanobiotix S.A. GAAP EPS of -€0.11, revenue of €26.6M - Seeking Alpha
- 7 days ago - NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results - GlobeNewsWire
- 7 days ago - Nanobiotix-J&J Therapy Shows Promise In Tough Head And Neck Cancer - Benzinga
- 8 days ago - NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC - GlobeNewsWire